<DOC>
	<DOCNO>NCT00003415</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug amifostine may protect normal cell side effect chemotherapy . PURPOSE : Phase I/II trial study effectiveness amifostine plus topotecan treating patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Amifostine Plus Topotecan Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate hematologic cytogenetic response treatment amifostine plus topotecan patient myelodysplastic syndrome . II . Evaluate toxic effect treatment patient . III . Evaluate effect treatment bone marrow recovery patient . OUTLINE : This dose escalation study topotecan . Patients receive amifostine IV follow topotecan IV 30 minute day 1-5 every 4-8 week least two course . Patients respond two course induction receive maintenance course every 6-8 week ten course absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat dose level topotecan . The maximum tolerate dose define dose 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A maximum 26 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm myelodysplatic syndrome ( MDS ) , diagnose least 3 month prior study enrollment , one follow subtypes : Refractory anemia excess blast ( RAEB ) RAEB transformation ( RAEBT ) Chronic myelomonocytic leukemia ( CMML ) CMML leukocytosis control hydroxyurea eligible absence neutropenia No treatment mutagenrelated MDS One cytopenia require : Untransfused hemoglobin le 10 g/dL and/or transfusiondependent ( require least four unit red blood cell prior 12 week ) Platelet count great 50,000/mm3 absolute neutrophil count le 1,000/mm3 No myelosclerosis occupy 30 % marrow PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : See Disease Characteristics No hereditary hemolytic disorder Transferrin saturation great 20 % Ferritin least 50 ng/mL Hepatic : Bilirubin le 3 mg/dL AST/ALT LDH less 2 time upper limit normal Renal : Creatinine le 2 mg/dL Cardiovascular : No significant cardiovascular disorder ( unrelated MDS ) No uncontrolled hypertension Pulmonary : No significant pulmonary disorder ( unrelated MDS ) Neurologic : No significant neurologic disorder ( unrelated MDS ) No history epilepsy Metabolic : No significant endocrine disorder ( unrelated MDS ) Other : Not pregnant nursing No significant gastrointestinal disease ( unrelated MDS ) GI blood loss No significant genitourinary system disease ( unrelated MDS ) No active infection require IV antibiotic therapy No serious illness medical condition Not HIV positive Not hepatitis B surface antigen positive No iron , vitamin B12 , folate deficiency No autoimmune disease No prior concurrent malignancy within 2 year except situ carcinoma cervix basal cell squamous cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent hematopoietic stimulant Chemotherapy : See Disease Characteristics At least 35 day since prior chemotherapy Endocrine therapy : No concurrent androgen therapy No concurrent corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : At least 35 day since previous therapy MDS ( transfusion ) No participation experimental clinical trial within 35 day entry current trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
</DOC>